Date: 2011-12-19
Type of information: Grant
Company: to-BBB (The Netherlands)
Investors: Agentschap NL (The Netherlands)
Amount: €600,000
Funding type: grant
Planned used: The financing will be used to support a brain drug delivery partnership with a top-5 pharma company.
Others: to-BBB, the Dutch brain drug delivery company, has been awarded a grant of over €600,000 through the “Internationaal Innoveren” program of the Dutch government agency Agentschap NL to support a brain drug delivery partnership with a top-5 pharma company. This work will facilitate future license deals with to-BBB’s brain cancer product 2B3-101 as well as other therapies in the pipeline.
The purpose of this collaborative project of to-BBB with a top-5 pharma company, and several additional scientific partners, is to deepen the understanding of the mechanisms that contribute to the increased uptake of specific drugs in the brain by use of the G-Technology. The project will provide data to support potential pharmaceutical license deals with to-BBB’s therapies.
Recently, to-BBB has initiated a clinical trial with its lead product 2B3-101 for primary and metastatic brain tumors. The trial is starting in specialized oncology centers in the Netherlands and Belgium with NKI-AVL, VUmc and LUMC currently open for recruitment. Recently, the plans for potential further clinical trials in the US were also successfully discussed with the FDA, in a pre-IND meeting.
The company’s second product, 2B3-201, is targeting neuroinflammation, which is known to play a role in many brain diseases including MS, epilepsy, Parkinson’s disease and ALS. Furthermore, to-BBB and NeuroVive are jointly developing a therapy for neuroprotection in stroke, traumatic brain injury and for prevention of ischemic brain complications in cardiac surgery.
Therapeutic area: Cancer - Oncology - Neurodegenerative diseases - Cardiovascular diseases
